| 1 |
35226525 | In patients with stroke or TIA and CYP2C19 loss-of-function alleles, ticagrelor vs. clopidogrel reduced 90-d stroke. | 2022 Mar |
1 |
| 2 |
35300607 | Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis. | 2022 Mar 17 |
4 |
| 3 |
35396752 | High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials. | 2022 Apr 9 |
1 |
| 4 |
32664772 | Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. | 2021 Jul 4 |
2 |
| 5 |
33744207 | Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. | 2021 Apr 12 |
5 |
| 6 |
32140798 | Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention. | 2020 Apr |
3 |
| 7 |
32266041 | Influence of CYP2C19 genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease. | 2020 May |
2 |
| 8 |
32320492 | Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis. | 2020 Aug |
2 |
| 9 |
32493215 | Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy. | 2020 Jun 3 |
1 |
| 10 |
32675750 | Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients. | 2020 Oct |
2 |
| 11 |
32840598 | Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. | 2020 Aug 25 |
2 |
| 12 |
33065552 | Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA. | 2020 Oct 16 |
1 |
| 13 |
33411687 | Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by CYP2C19 metabolizer status: subgroup analysis of the PRINCE trial. | 2020 Dec 19 |
1 |
| 14 |
33551797 | Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. | 2020 |
1 |
| 15 |
30936830 | Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects. | 2019 |
1 |
| 16 |
31141104 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. | 2019 Jul 1 |
2 |
| 17 |
31171523 | Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. | 2019 Jun 6 |
1 |
| 18 |
28117433 | Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. | 2018 Jan |
1 |
| 19 |
28689434 | Role of genetic testing in patients undergoing percutaneous coronary intervention. | 2018 Feb |
1 |
| 20 |
28260316 | [Impact of CYP2C19 genotypes on antiplatelet therapy among Chinese patients with acute myocardial infarction after percutaneous coronary intervention]. | 2017 Feb 24 |
1 |
| 21 |
28783717 | Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI). | 2017 Aug 7 |
1 |
| 22 |
27977637 | Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes. | 2016 Dec 15 |
2 |
| 23 |
25823779 | Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. | 2015 |
1 |
| 24 |
26108379 | Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention. | 2015 Jul |
2 |
| 25 |
26398625 | CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. | 2015 Dec |
1 |
| 26 |
26447442 | Pharmacogenetics: Using Genetic Information to Guide Drug Therapy. | 2015 Oct 1 |
1 |
| 27 |
26550258 | A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes. | 2015 |
4 |
| 28 |
24406062 | Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. | 2014 Jan |
1 |
| 29 |
24856643 | Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. | 2014 Jul |
1 |
| 30 |
24279856 | Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. | 2013 Dec |
1 |
| 31 |
21177984 | In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. | 2011 Apr |
1 |
| 32 |
21079055 | First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. | 2010 Dec |
2 |